Lynparza
Top Five Articles on GenomeWeb Last Week: Illumina, BillionToOne, Foundation Medicine, Qiagen, More
Last week, GenomeWeb's readers were most interested in news about Illumina pricing a $500 million public notes offering.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.